Opinion|Videos|December 4, 2024
The Clinical and Economic Impact of LEMS in SCLC Care
Author(s)Wade Iams, MD
Key Takeaways
- Disparities in healthcare access can lead to delayed diagnosis and suboptimal treatment of LEMS in small cell lung cancer patients, affecting outcomes.
- Quantifying the economic burden of LEMS requires evaluating direct medical costs, indirect costs, and patient out-of-pocket expenses.
A medical expert discusses how disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer, how health care providers can quantify the economic burden of LEMS on both patients and health care systems, the role of patient-reported outcomes in providing deeper insights into the clinical and economic burden of LEMS, and how health systems can utilize real-world data to better understand the indirect costs of LEMS.
Episodes in this series
Video content above is prompted by the following:
- How do disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer?
- How can health care providers quantify the economic burden of LEMS on both patients and health care systems?
- In what ways can patient-reported outcomes provide deeper insights into the clinical and economic burden of LEMS?
- How can health systems utilize real-world data to better understand the indirect costs of LEMS?
Related to this article
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Trending on AJMC
1
Surrogate End Points, Drug Costs Complicate Oncology Formularies
2
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
3
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
4
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
5